Bausch Health vs. Taro Pharmaceuticals: Consent Judgment in Duobrii® Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bausch Health Ireland, Ltd. v. Taro Pharmaceuticals, Inc. |
| Case Number | 2:22-cv-04670 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jul 2022 – Apr 2024 624 Days |
| Outcome | Plaintiff Win — Consent Judgment |
| Patents at Issue | |
| Accused Products | Taro’s proposed generic of Duobrii® (halobetasol propionate/tazarotene lotion) |
Case Overview
The Parties
⚖️ Plaintiff
Multinational specialty pharmaceutical company with a substantial branded dermatology portfolio, commercializing Duobrii® for plaque psoriasis.
🛡️ Defendant
Generic and specialty pharmaceutical manufacturer whose ANDA filing for a generic version of Duobrii® triggered the patent infringement claims.
Patents at Issue
This landmark case involved four U.S. patents collectively covering aspects of the halobetasol propionate and tazarotene combination formulation, including composition, therapeutic use, and manufacturing-related claims within the dermatological treatment space. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • U.S. Patent No. 8,809,307 B2 — Composition and use claims for halobetasol propionate and tazarotene formulation
- • U.S. Patent No. 10,426,787 B2 — Method of treating plaque psoriasis using the combination formulation
- • U.S. Patent No. 10,478,502 B2 — Formulation stability and manufacturing-related claims
- • U.S. Patent No. 10,251,895 B2 — Specific concentration ranges and therapeutic regimens
Developing a generic drug or new formulation?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded through a Consent Judgment, a negotiated resolution in which both parties agreed to a court-entered judgment without proceeding to a contested trial. The specific terms of the consent judgment—including any agreed-upon entry dates for Taro’s generic product, royalty arrangements, or injunctive provisions—were not publicly disclosed. The civil case was formally terminated upon entry of the consent judgment.
Key Legal Issues
The infringement action was brought under the Hatch-Waxman Act framework, wherein Taro’s filing of an ANDA with Paragraph IV certifications against the asserted Bausch Health patents constituted a statutory act of infringement under 35 U.S.C. § 271(e)(2). Bausch Health’s assertion of four patents across multiple application lineages reflects a deliberate portfolio-layering strategy—covering different claim types and filing dates to create overlapping protection that increases litigation complexity and negotiating leverage for the branded manufacturer.
Freedom to Operate (FTO) Analysis for Pharma & Biotech
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic area
- See which companies are most active in dermatology IP
- Understand claim construction patterns for combination therapies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Combination therapies (e.g., Duobrii®)
4 Patents Asserted
Complex multi-patent litigation
FTO is Critical
Before ANDA or new product launch
✅ Key Takeaways
Consent judgments in Hatch-Waxman cases preserve portfolio integrity while managing claim construction risk.
Search related case law →Four-patent assertion strategies increase settlement leverage by expanding the invalidity and non-infringement burden for defendants.
Explore precedents →Frequently Asked Questions
Four U.S. patents were asserted: U.S. 8,809,307 B2; U.S. 10,426,787 B2; U.S. 10,478,502 B2; and U.S. 10,251,895 B2, all protecting aspects of the Duobrii® halobetasol propionate/tazarotene combination formulation.
The parties reached a negotiated resolution without proceeding to trial. The specific commercial terms were not publicly disclosed. The case was formally terminated via consent judgment on April 5, 2024.
It reinforces multi-patent portfolio assertion as an effective Hatch-Waxman litigation strategy and highlights New Jersey as a premier venue for specialty pharmaceutical patent disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 2:22-cv-04670 (D.N.J.)
- USPTO Patent Full-Text Database
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.